William H. Bradley

Froedtert Hospital — United States

Medicine · Health Sciences

29h-index8.2kcitations173works6.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(75), PARP inhibition in cancer therapy(30), Endometrial and Cervical Cancer Treatments(22), BRCA gene mutations in cancer(13), Uterine Myomas and Treatments(10)

Publications173 total

Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.
PubMed·2026
CLINICAL ACTIVITY OF ACR-368 IN PATIENTS WITH ENDOMETRIAL CARCINOMA PROSPECTIVLY SELECTED BY ONCOSIGNATURE – A PHASE 2 STUDY - ACR-368-201/GOG3082 (NCT05548296)
International Journal of Gynecological Cancer·2026
Rucaparib maintenance in ATHENA-MONO (GOG-3020/ENGOT-ov45) in patients with newly diagnosed advanced ovarian cancer: exploratory post-progression evaluations for patients with HRD-negative and HRD-unknown tumours
International Journal of Gynecological Cancer·2026
Robotic management of complex traumatic hernias: A single-center experience
Surgery·2025
Corrigendum to “OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer” [Gynecol Oncol 2025 Jun 197 182–191]
Gynecologic Oncology·2025Open Access
567 XTX301, a tumor-activated Interleukin-12 (IL-12), demonstrated IL-12 pharmacology in patients with advanced solid tumors: pharmacodynamic data from first-in-human phase 1 study (NCT05684965)
Regular and Young Investigator Award Abstracts·2025Open Access
1234eTiP OVATION-3: A randomized phase III trial evaluating the safety and efficacy of intraperitoneal IL-12 gene therapy administered in combination with standard neoadjuvant and adjuvant chemotherapy (N/ACT) in newly-diagnosed patients with advanced epithelial ovarian cancer (EOC)
Annals of Oncology·2025
Identifying extracellular vesicle-based biomarkers that distinguish responders from non-responders in EndoBARR clinical trial patients
Gynecologic Oncology·2025
105P Immune biomarker analysis of the OVATION-2 trial, a randomized phase I/II study of IL-12 gene therapy IMNN-001 in combination with neo/adjuvant chemotherapy (NACT) in newly-diagnosed advanced epithelial ovarian cancer (EOC)
ESMO Open·2025Open Access
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
Gynecologic Oncology·2025· 3 citedOpen Access
A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.
Journal of Clinical Oncology·2025· 1 cited
Supplementary Table 1 from GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
2024Open Access
Data from GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
2024Open Access
Supplementary Figure 1 from GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
2024Open Access
Mental health in gynecologic oncologists: Unmet needs, barriers to care, and possibilities for improvement
Gynecologic Oncology·2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology·2024· 117 citedOpen Access
LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
Annals of Oncology·2024· 2 citedOpen Access
Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer
Frontiers in Oncology·2024· 1 citedOpen Access
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for <i>BRCA</i> wild‐type, platinum‐sensitive, recurrent ovarian cancer
Cancer·2024· 6 citedOpen Access
PO13
Brachytherapy·2023· 1 cited
page 1 of 9Next →

Frequent Co-authors

Antonio González-Martı́n(16), Carol Aghajanian(13), Kathleen N. Moore(12), Giovanni Scambia(12), Paul DiSilvestro(12), Nicoletta Colombo(11), Ana Oaknin(11), Michael Friedländer(11), Alla Lisyanskaya(11), Gabe S. Sonke(11), Charlie Gourley(11), Susana Banerjee(11), Amit M. Oza(11), Anne Floquet(10), Alexandra Léary(10), Elizabeth Lowe(10), Byoung‐Gie Kim(8), Cara Mathews(7), Joyce F. Liu(7), Ralph Bloomfield(5)